Investor flows are rotating away from last year’s AI/high‑growth leaders—Meta has fallen more than 20% in the past three months and is only up ~2% YTD, Nvidia’s YTD gain of >35% has largely stalled since July, and Tesla remains volatile—toward healthcare, which is gaining traction on a combination of GLP‑1 drug success and a recent federal deal to expand Medicare/Medicaid access, cheaper valuations (healthcare ~16x forward vs. tech >30x), and defensive inflows not seen since early 2021. Market technicals also show profit‑taking in AI (many tech names below their 20‑day moving averages), supporting a potential sustained sector rotation. Standout large‑caps cited as leaders are Eli Lilly (GLP‑1s Mounjaro/Zepbound, Phase‑3 oral GLP‑1, Q3 beats and policy tailwinds), Merck (trading at ~10x forward, Keytruda sales +8% YoY, Q3 revenue >$17bn) and AbbVie (up >30% YTD, SKYRIZI sales $4.7bn +46% YoY, RINVOQ $2.2bn +34% YoY and raised 2026 outlook), suggesting select healthcare names could offer attractive risk/reward as the rotation is still in its early innings.
Market internals show a clear rotation away from 2023–24 AI/high-growth leaders toward defensive healthcare exposure: Meta is down more than 20% over the last three months and only up ~2% YTD, NVIDIA remains >35% YTD but has delivered only ~3% of that gain since July, and Tesla exhibits continued volatility. Technicals support profit-taking in tech, with a majority of AI names trading below their 20‑day moving averages, while healthcare is registering inflows not seen since early 2021. Healthcare’s re‑rating is driven by policy and fundamental catalysts: GLP‑1 drugs have created substantial revenue upside and a recent federal deal expands Medicare/Medicaid access at reduced prices, healthcare trades at ~16x forward earnings versus tech >30x, and the sector showed defensive strength during the Q1 2025 bear market. These factors create a valuation and safety differential that could sustain further rotation if earnings and policy execution continue. Company‑level leadership is concentrated in a few large caps with clear catalysts. Eli Lilly rebounded after Q3 top‑ and bottom‑line beats, GLP‑1 commercial traction (Mounjaro, Zepbound) and a Phase‑3 oral GLP‑1 program; Merck trades at roughly 10x forward earnings despite Keytruda sales +8% YoY and Q3 revenue above $17 billion; AbbVie is up >30% YTD with SKYRIZI $4.7bn (+46% YoY), RINVOQ $2.2bn (+34% YoY) and an upgraded 2026 outlook, while still trading near 19x forward earnings.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Overall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
